Skip to main content

Table 2 Risk of cancer after SLE cohort entry compared to general population controls (N = 2431 SLE patients contributing 20,399 person-years)#

From: Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection

Site No. obs. No. exp. SLE cohort SIR (95%CI) p value AA* SIR (95%CI) AA p value Non-AA^ SIR (95%CI) Non-AA p value
All 119 102.3 1.16 (0.96–1.39) 0.12 1.63 (1.26–2.08) < 0.001 0.86 (0.65–1.13) 0.31
Female cancers
 Breast 22 34.9 0.63 (0.39–0.95) 0.027 1.13 (0.65–1.84) 0.69 0.29 (0.11–0.63) < 0.001
 Cervix 11 4 2.73 (1.36–4.89) 0.006 3.78 (1.52–7.79) 0.006 1.84 (0.50–4.71) 0.35
 Vagina/vulva 13 1.9 6.87 (3.66–11.8) < 0.001 14.13 (7.05–25.3) < 0.001 1.80 (0.22–6.49) 0.61
Other cancers
 Hematologic 10 6.5 1.54 (0.74–2.84) 0.24 1.87 (0.61–4.36) 0.27 1.31 (0.43–3.07) 0.67
 Lung 11 8.7 1.27 (0.63–2.26) 0.52 1.84 (0.74–3.80) 0.18 0.82 (0.22–2.09) 0.92
 Colorectal 10 7.2 1.39 (0.66–2.55) 0.38 1.18 (0.32–3.01) 0.88 1.57 (0.58–3.42) 0.37
 Thyroid 9 4 2.27 (1.04–4.30) 0.041 0.00 (0–3.31) 0.66 3.15 (1.44–5.98) 0.006
 Melanoma 8 5.4 1.48 (0.64–2.91) 0.36 0.00 (0–37.3) 0.99 1.51 (0.65–2.97) 0.34
HPV-associated cancers** 26 5.9 4.39 (2.87–6.44) < 0.001 7.23 (4.35–11.3) < 0.001 2.13 (0.86–4.38) 0.10
  1. Data for cancer sites with < 5 cases observed after cohort entry are not presented, including the uterus, ovary, fallopian tube, prostate, multiple myeloma, salivary gland, stomach, duodenal and other small bowel, anus, pancreas, liver, kidney, bladder, brain, and unknown primary
  2. **HPV-associated cancers include cervix, vulva/vagina, and anus cancers
  3. AA = African American; non-AA = non-African American
  4. *N = 966 SLE patients contributing 8488 person-years
  5. ^N = 1465 SLE patients contributing 11,911 person-years
  6. #When adjusting for multiple comparisons (10 per racial strata), p ≤ 0.005 is considered statistically significant